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Abstract
Background: We aimed to investigate the state of cardiovascular risk/protection factors in early psychosis patients.
Methods: A total 119 subjects were recruited during the first year after their first episode of psychosis. Eighty-five of these subjects 
were followed during the next 6 months. Cardiovascular risk/protection factors were measured in plasma and co-variated by 
sociodemographic/clinical characteristics. Multiple linear regression models detected the change of each biological marker 
from baseline to follow-up in relation to clinical scales, antipsychotic medication, and pro-/antiinflammatory mediators.
Results: Glycosylated hemoglobin is a state biomarker in first episode of psychosis follow-up patients and inversely correlated 
to the Global Assessment of Functioning scale. We found opposite alterations in the levels of VCAM-1 and E-selectin in first 
episode of psychosis baseline conditions compared with control that were absent in the first episode of psychosis follow-up 
group. Adiponectin levels decreased in a continuum in both pathological time points studied. E-Selectin plasma levels were 
inversely related to total antipsychotic equivalents and adiponectin levels inversely co-related to the Global Assessment of 
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Functioning scale. Finally, adiponectin levels were directly related to antiinflammatory nuclear receptor PPARγ expression in 
first episode of psychosis baseline conditions and to proinflammatory nuclear factor nuclear factor κB activity in follow-up 
conditions, respectively.
Conclusions: Our results support the need for integrating cardiovascular healthcare very early after the first episode of 
psychosis.
Keywords: cardiovascular diseases, first episode, risk factors, neuroimmunology, antipsychotics
Introduction
Increasing evidence supports the potential benefits of early 
intervention to enable disease prevention and to improve prog-
nosis in psychiatric disorders, this being particularly important 
in schizophrenia (SZ) (Perala et  al., 2007; van Os and Kapur, 
2009). To consolidate this intervention, a deeper scientific effort 
is needed to properly identify and characterize the early phase 
of the disease (Cheng and Schepp, 2016). The First Episode of 
Psychosis (FEP) is classically considered the onset of the disease 
or, at least, the moment of the first presentation of psychotic 
symptoms, typically during late adolescent or early adult years. 
At this initial stage, the number of confounding variables pro-
duced by chronicity and medication is lower and consequently, 
the search for risk/protective biomarkers directly related to the 
etiopathogenesis of the disease is favored (Fond et al., 2015).
Chronic disease-induced lifestyle and the long-term use 
of antipsychotic medication are factors directly related to the 
appearance of comorbid metabolic disorders and cardiovascular 
(CV) alterations in the symptomatology of SZ, which are consid-
ered one of the main causes of premature death (Ringen et al., 
2014). Specifically, chronic use of antipsychotics can induce 
metabolic alterations (weight gain, obesity, diabetes, hypergly-
cemia, dyslipidemia, and metabolic syndrome) directly related 
to an increased risk of suffering CV pathologies (Feinstein, 2002; 
Casey et  al., 2004). However, even at the early stage of illness 
around FEP, metabolic abnormalities related to the first year of 
antipsychotic medication have been reported (Perez-Iglesias 
et al., 2014) as well as increased CV risk in patients with first-
episode SZ spectrum disorders (Correll et al., 2014). In a more 
recent prospective and naturalistic study (Bioque et  al., 2017), 
antipsychotic polypharmacy (and other factors) have been 
related to the extremely high risk for patients at early phases of 
SZ and other psychotic disorders of developing CV comorbidity, 
as well as the rapid worsening of the metabolic profile during 
the first 2 years.
The effects of antipsychotic drugs seem to be more pronounced 
at the onset of treatment (as soon as 8–12 weeks after initiation) 
in young antipsychotic-naive patients after FEP, including body 
weight gain and body mass index (BMI) increase (Pramyothin and 
Khaodhiar, 2010). However, there is growing evidence regarding the 
existence of subtle metabolic/CV alterations in drug-naïve psych-
otic populations or FEP subjects exposed to antipsychotics for a 
short, known period (2–4 weeks), suggesting the role of alternative 
susceptibility factors and premature etiopathogenic mechanisms 
not exclusively dependent on unhealthy lifestyle or antipsychotic 
medication. Thus, some authors have reported that drug-naïve, 
FEP patients are more insulin resistant (as assessed by the homeo-
static model assessment index) compared with healthy controls 
(Petrikis et al., 2015). Lipid metabolism and abnormal QTc inter-
val prolongation could also be affected in drug-naïve FEP patients 
(Zhai et al., 2017a, 2017b). The existence of concomitant individual 
risk factors in some FEP subjects such as subtle changes in hyper-
tension, hypertriglyceridemia, abdominal obesity, and hypergly-
cemia without higher baseline metabolic syndrome prevalence 
compared with the general population of similar age needs to be 
further corroborated (Fleischhacker et al., 2013).
However, some discrepancy exists, and some studies did not 
find increased metabolic syndrome prevalence in naïve patients 
with a first episode of nonaffective psychosis compared with 
matched normal population (Garcia-Rizo et  al., 2016). Other 
authors have found similar results reporting no signs of insulin 
resistance and dyslipidemia in drug-naïve FEP patients (Sengupta 
et al., 2008; Chen et al., 2013). Some meta-analysis concluded that 
there is no difference in CV risk assessed by weight gain or clas-
sical metabolic indices between individuals with an untreated 
FEP and matched controls (Foley and Morley, 2011).
These discrepant results suggest the need to search for novel 
metabolic alterations at a molecular level for the identification 
and early intervention of metabolic and CV risk in drug-naïve 
psychosis patients or FEP subjects exposed to antipsychotics 
for a short, known period of time. The search for systemic bio-
markers for the early identification of individuals likely to suffer 
metabolic/CV alterations or to evaluate their future response to 
antipsychotics is continuously growing and crosslinks with other 
disciplines, as is the study of innate immunity/inflammation.
Inflammation is receiving special attention as an import-
ant component in the physiopathology of metabolic and CV 
disorders. Certain inflammatory mediators have been consid-
ered as potential biomarkers for these pathologies (Fortmann 
et al., 2004). In fact, there are consolidated (i.e., high-sensitivity 
C-reactive protein levels, cytokines) and emerging inflamma-
tory markers for CV risk (Lubrano and Balzan, 2015) that need to 
be further characterized, considering the evidence for elevated 
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systemic inflammation in patients with FEP and SZ (Garcia-
Bueno et al., 2014a, 2014b; Leza et al., 2015).
Candidates to survey in FEP are cell adhesion molecules, 
including VCAM-1 and the selectins (P, E, and L), inflammatory 
markers implicated in the etiology and physiopathology of ath-
erosclerosis, and therefore metabolic syndrome and CV disease 
(Brevetti et  al., 2006). Recently abnormal VCAM-1 and selectin 
levels have been reported in SZ, being suggested as biomarkers 
for endothelial dysfunction (Nguyen et al., 2017). The capacity of 
atypical antipsychotics such as risperidone to upregulate V-CAM 
and selectin levels contributing to worsening endothelial function 
in diabetic rats has been also reported (Aboul-Fotouh and Elgayar, 
2013). Another relevant mediator is the adipocytokine adiponec-
tin, a master regulator of glucose metabolism and fatty acid oxida-
tion and currently considered as a link between the inflammatory 
response and lipid metabolism. Reduced levels of adiponectin 
have been related to metabolic disorders such as obesity, insulin 
resistance, and type 2 diabetes (Shibata et al., 2017). Furthermore, 
several authors have reported decreased adiponectin levels also in 
mental disorders (Wedrychowicz et al., 2014).
Based on this background, we aimed to investigate the state of 
the inflammatory-related mediators VCAM-1, E-selectin, and adi-
ponectin, considered to be putative CV risk/protective risk factors, 
in plasma samples of FEP patients from the Flamm-PEPs study. 
This is a multicenter, longitudinal, naturalistic, follow-up study 
designed to evaluate systemic inflammatory alterations inside 
the Spanish national network for mental health research (Garcia-
Bueno et  al., 2014a, 2014b). In this study, we applied previously 
validated robust multiple linear regression models to further ana-
lyze the change in every biological marker in relation to clinical 
characteristics classically related to increased metabolic and CV 
risk, confounding factors as diverse antipsychotic medication, and 
pro-/antiinflammatory mediators previously described in these 
same control, baseline, and 6-month follow-up FEP patients.
Materials and Methods
Subjects
We recruited a total of 119 FEP subjects during the first year after 
their FEP according to the DSM-IV criteria (American Psychiatric 
Association, 1994) in 5 tertiary hospitals in Spain as well as 108 
gender-, ethnicity-, and age-matched controls between September 
2010 and June 2011. From the initial sample, 85 FEP subjects were fol-
lowed for the next 6 months (maximum 12 months after inclusion). 
In adults, the diagnosis was established by expert clinicians using 
the semistructured diagnostic interview designed to assess current 
and past psychopathology and personality disorders, according to 
DSM-IV criteria (SCID-I and II). For subjects <18 years old, diagno-
sis was made using the Spanish translation of the Kiddie-Schedule 
for Affective Disorders and SZ, Present and Lifetime Version (Ulloa 
et al., 2006). The duration of untreated psychosis (DUP) was defined 
as the number of days elapsed between the onset of positive 
psychotic symptoms (the first week with the PANSS items P1, P3, 
P5, P6, or G9 score ≥4) and the first appropriate treatment for psych-
osis. Being a naturalistic study, there were no specific guidelines 
for treatments, so patients received antipsychotic treatment based 
on the clinician’s choice. Dosing, co-medications, or treatment 
changes were based on clinical necessity. Following the inclusion/
exclusion criteria, treatment with antipsychotics did not exceed 
12 months at study entry (Bernardo et al., 2017).
Multiple sources, including medical records and interviews 
with relatives, were used to ascertain the length of this period. The 
initial number of recruited subjects, the final number of those to 
fulfill both clinical and the whole analytical study, and site recruit-
ment details are shown in the supplementary information. This 
cohort was considered as the FEP baseline group. FEP subjects 
were followed up for 6 months (maximum 12 months after inclu-
sion), and this cohort was considered as the FEP follow-up group.
Baseline and follow-up demographic details of patients and 
controls involved in the study are detailed in Table  1. In brief, 
mean age was 24.21 ± 6.08  years, with a greater percentage of 
males (70.6%). To ensure diagnosis stability, clinical evaluations 
were repeated after 6 months of the patient’s inclusion. Tto not 
exclude early-onset psychotic patients, there was a broad age of 
inclusion allowed. The inclusion criteria for patients were: (1) age 
between 7 and 35 years at the time of first evaluation; (2) pres-
ence of psychotic symptoms of <12 months’ duration; (3) ability 
to speak Spanish correctly; and (4) signed the informed consent. 
The exclusion criteria for patients were: (1) mental retardation 
per the DSM-IV criteria, including not only an IQ <70 but also 
impaired functioning; (2) history of head trauma with loss of con-
sciousness; and (3) organic disease with mental repercussions.
Healthy controls were selected from the same geographic areas. 
The inclusion criteria for controls were: (1) same gender as patients; 
(2) similar age (± 10%) as patients; (3) similar socioeconomic status 
as patients, measured by the Hollingshead-Redlich scale (± 1 level); 
(4) no past or present psychiatric disorder per DSM-IV criteria; (5) 
ability to speak Spanish correctly; and (6) signed the informed con-
sent. The exclusion criteria for controls were: (1) mental retardation 
according to DSM-IV criteria (American Psychiatric Association 
(Washington), 1994) including not only an IQ <70 but also impaired 
functioning; (2) history of head trauma with loss of consciousness; 
(3) organic disease with mental repercussions; and (4) history of 
psychotic disorder among first-degree relatives.
Clinical assessment of patients and controls included a 
complete medical history and physical examination, laboratory 
tests (thyroid function, liver function, renal function, electrolyte 
levels, complete blood cell count, and urinalysis), and electro-
cardiogram. Anthropometric measures were assessed: weight, 
height, and BMI (weight in kg/height2). A complete description 
of the clinical protocol has been published elsewhere (Bioque 
et  al., 2017). The exclusion criteria were ongoing infections, 
fever, allergies, or the presence of other serious medical con-
ditions (autoimmune, cardiac, pulmonary, endocrine, chronic 
infectious diseases, neoplasms). Having designed a real-life 
patient, naturalistic study, substance use was not an exclusion 
criterion. Neither the FEP patients nor the healthy control sub-
jects received immunosuppressive drugs or vaccinations for at 
least 6 months prior to inclusion in the study or antiinflamma-
tory analgesics the 2 days prior to the blood sample.
The study was approved by the ethics committees of the 5 
participant hospitals. The subjects participated after receiving 
a full explanation of the study and providing written, informed 
consent in accordance with the Declaration of Helsinki II.
Specimen Collection and Preparation
Venous blood samples (10  mL) were collected by nursing per-
sonnel in polypropylene EDTA-containing tubes in the morn-
ing (between 8:00 and 10:00 am) after fasting overnight. All the 
sample collection and preparation protocols were approved by 
the technical committee of the Flamm-PEPs study (available on 
www.cibersam.es). The fresh blood samples were maintained at 
4ºC until preparation after approximately 1 hour.
Blood tubes were centrifuged (641 x g for 10 minutes, 4ºC). The 
resultant plasma samples were carefully collected and stored at 
-80ºC until further action was required.
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Biochemical Determinations in Plasma
VCAM-1, E-Selectin, and adiponectin levels were measured by 
enzyme-linked immunosorbent assay following the manu-
facturer’s instructions. Plasma samples were diluted 1:200 for 
VCAM-1 and 1:100 for E-Selectin determinations with the assay 
diluent included in the commercial kits (RayBio). The sensitiv-
ity of the assay for VCAM-1 was 0.3  ng/mL and 30 pg/mL for 
E-Selectin; intra- and inter-assay CVs were <10% and <12%, 
respectively, in both kits. Plasma samples were diluted 1:5151 
Table 1. Demographic and Clinical Characteristics
Patients Baseline (b)
Patients Follow- 
up (f) p value (b-f) Controls ( c) P value (b-c) P value (f-c)
N 85 85 106
Age-years 24,21(6,028) 25,21 (6,028) 25,43(6,428) 0,21
Sex- nº(%)
Male 60(70,6) - 70(66,0) 0,503
Female 25(29,4) - 36(34,0)
Age of psychosis onset 24,37(5,93) -
Socioeconomic Status
High 16(18,8) - 14(13,2) 0,01
Medium-High 7(8,2) - 17(16,0)
Medium 30(35,3)* - 54(50,9)
Medium-Low 24(28,2) - 19(17,9)
Low 8(9,4)* - 2(1,9)
Ethnic group
Caucasian 79(92,9) - 96(90,6) 0,344
Gipsy 1(1,2) - 0(0,0)
Maghrebian 1(1,2) - 2(1,9)
Asian 1(1,2) - 0(0,0)
Caribbean 1(1,2) - 0(0,0)
Hispanic 2(2,4) - 6(5,7)
Others 0 (0,0) - 2(1,9)
Diagnosis nº(%)
Affective Psychosis* 17(20) 17(20) 0,026 -
Non-affective Psychosis 68(80) 62(72,9) -
Drugs Psychosis 0(0,0) 0(0,0) -
No psychosis 0(0,0) 6(7,1) -
Psychopathology score
PANSS POSITIVE 10,67(5,379) 8,01(5,032) <0,001 -
PANSS NEGATIVE 14,58(6,27) 11,76(8,149) 0,001 -
PANSS GENERAL 26,47(9,75) 20,524(11,9) <0,001 -
PANSS TOTAL 51,72(19,23) 40,29(23,6) <0,001 -
YOUNG 1,45(3,25) 1,39(3,5) 0,711 -
Montgomery-Asberg 6,51(6,52) 5,75(6,71) 0,096 -
Global functioning score (GAF) 68,60(13,88) 72,08(17,22) 0,005 -
DUP 68,58(77,29) -
Antipsycohotic medications - n(%)
None 17(20,0) 21(25,9) -
Risperidone 30(35,3) 21(25,9) -
Aripiprazole 9(10,6) 15(18,5) -
Olanzapine 9(10,6) 6(7,4) -
Quetiapine 6(7,1) 5(6,2) -
Clozapine 5(5,9) 6(7,4) -
Ziprasidone 2(2,4) 2(2,5) -
Paliperidone 7(8,2) 5(6,2) -
DDD 282,19(253,04) 298,06(303,16) 0,903 -
Lithium n(%) 8(9,4) 7(8,2) 0,824 -
Body mass index 24,83(3,92)* 24,65(5,73) 0,06 23,14(3,16) 0,002 0,003
Tobacco use per month, n cigarettes 238,9(259,08)* 241,98(254,1) 0,881 45,38(119,3) <0,001 <0,001
Cotinine, ng/ml 86,73(84,46) 97,28(84,50) 0,192 26,28(49,31) <0,001 <0,001
Cotinine, ng/ml
minor PC n(%) 31(39,7) 29(34,9) 0,529 60(70,6) <0,001 <0,001
major PC n(%) 47(60,3) 54(65,1) 25(29,4)
CANNABIS use n(%) 18(21,2)* 4(5,1) 0,003 14(15,9) 0,372 0,325
CANNABIS use per month, n cigarettes 4,71(19,36) 1,09(6,37) 0,092 1,15(6,36) 0,657 0,345
DUP: duration of untreated psychosis.
DDD: Defined daily dose of chlorpromazine equivalents (mg).
* Affective psycho.sis includes DSM-IV diagnosis of unipolar depression or bipolar disorder with psychotic features and schizoaffective disorder.
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for determinations of total and high-molecular adiponectin 
fraction levels (Alpco). The detection limit was 0.019  ng/mL; 
intra- and inter-assay CVs were 5.4% and 5.0%, respectively. The 
absorbance measurements were determinate in the multi-mode 
plate reader Synergy 2 (BioTek).
Metabolic and CV risk parameter data of the subjects 
included in our study were already published as a part of the 
PEPs Project, which recruited 335 FEP subjects and 253 matched 
healthy controls (Bioque et al., 2017). Briefly, in all the participat-
ing sites, blood glucose, total cholesterol, high density lipopro-
tein (HDL) cholesterol, low density lipoprotein cholesterol, and 
triglycerides were directly analyzed by enzymatic procedures 
with an Automatic Chemical Analyzer. Glycated hemoglobin 
was analyzed by high-performance liquid chromatography. 
The reference values at each site were recorded in a common 
database called GIDSAM, where individual values were homog-
enized and included (Bernardo et al., 2013).
Proinflammatory/antiinflammatory parameters data of 
the subjects included in our study were previously published 
(Garcia-Bueno et al., 2014a, 2014b).
Statistical Analysis
Differences between demographic, clinical, and biological mark-
ers for patients and controls were assessed using chi-square, t 
test, nonparametric Mann-Whitney U or Wilcoxon tests accord-
ing to the distribution and scales of the variables. To calculate 
the association between the level of biological markers and 
FEP, multiple linear regression models were used in which we 
controlled for potential confounders (age, gender, CV history, 
cannabis, and tobacco use per month). Multiple linear regres-
sion analysis was used to analyze the change in each biological 
marker depending on the change in demographic (gender, age), 
clinical variables (CV history, lithium, DUP, GAF), antipsychotic 
medication (defined daily dose [DDD] and types), and cannabis 
and tobacco (cotinine). Correlations were analyzed to evaluate 
the association between biological markers and pro-/antiin-
flammatory parameters.
Results
Demographic and Clinical Features
The demographic and clinical characteristics of the FEP patients 
and the healthy control group are presented in Table 1 and can be 
also found in a previous study evaluating the status of systemic 
inflammation in the same groups of control and FEP subjects 
(Garcia-Bueno et al., 2014a, 2014b). Both baseline and follow-up 
FEP patients differed in BMI compared with matched controls 
(BMI, respectively; 24.83 ± 3.92; 24.65 ± 5.73 vs 23.14 ± 3.16, P = .002; 
P = .003). Another important characteristic of our cohorts is the 
different type of antipsychotic medication used. In baseline FEP 
conditions, only 9 patients (10.6%) were treated with olanzapine 
and 6 (7.1%) with quetiapine. In the follow-up group, 6 (7.4%) 
received olanzapine and 5 (6.2%) quetiapine. PANSS and GAF 
clinical scales showed significantly less severe symptomatology 
in the follow-up group compared with baseline FEP condition.
Metabolic and CV Alterations in FEP Baseline and 
Follow-Up Groups
Firstly, we explored the general state of typical metabolic and CV 
parameters in the 3 groups of subjects studied. Bivariate ana-
lysis found a significantly higher basal triglyceride levels and 
abdominal perimeter in the FEP baseline group compared with 
controls, while HDL cholesterol values appeared lower in the 
pathological baseline group (Table 2). In the follow-up group, all 
these alterations remained present, and a significant increase 
in glycosylated hemoglobin was also found (Table 2). Baseline 
and follow-up groups only differed in glycosylated hemoglobin 
levels that were lower in baseline group (Table 2).
Novel CV Risk/Protective Factors in FEP Baseline and 
Follow-Up Groups
Next, we aimed to evaluate whether there were alterations in 
the plasma levels of the putative metabolic and CV risk (VCAM-
1, E-Selectin) and protective (adiponectin, both in its high 
molecular weight [HMW] and total) markers between control, 
baseline, and follow-up groups.
Bivariate analysis showed that VCAM-1 levels were signifi-
cantly lower in the baseline group compared with the con-
trol group (Table 2; Figure 1A). This effect was partly due to an 
absence in the follow-up group, returning to values near con-
trol levels (Table 2; Figure 1A). In the case of the other adhesion 
molecule E-selectin, the pattern was the opposite. The baseline 
group’s E-selectin plasma levels were higher than control sub-
jects (Table 2; Figure 1B). This effect was significantly reversed 
in the follow-up conditions, returning to control levels (Table 2; 
Figure 1B).
HMW and total adiponectin plasma levels were mark-
edly lower in the follow-up group compared with both control 
and baseline groups, with no differences found between them 
(Table 2; Figure 1C-D).
In summary, we found opposite alterations to the levels of 
the CV risk factors VCAM-1 and E-selectin in FEP baseline condi-
tions compared with control. These alterations were no longer 
present in the FEP follow-up group. In the case of the protective 
factor adiponectin, its HMW and total plasma levels were lower 
at both pathological time points studied.
Effects of Demographic and Clinical Features 
on Altered Metabolic and CV Parameters in FEP 
Baseline and Follow-Up Groups
Our next goal was to evaluate through ANCOVA the possible 
influence of selected demographic and clinical characteristics 
only on the significant alterations observed by bivariate analysis 
in general metabolic and CV risk factors and novel CV risk/pro-
tective parameters in control and FEP subjects.
When comparing control and FEP baseline groups, all the 
alterations previously found in the bivariate analysis remained 
significant (BMI, E-Selectin, triglyceride, and HDL cholesterol 
levels and abdominal perimeter) except for the effect observed 
in VCAM-1 levels (see supplemental Table 1A). In addition, BMI 
was directly affected by gender (higher in males) and the exist-
ence of familiar CV clinical record (supplemental Table  1A). 
Triglyceride levels were also directly related to age and coti-
nine levels (tobacco consumption) in plasma (supplemental 
Table 1A). Finally, abdominal perimeter was directly related to 
gender (higher in males), age, and familiar CV clinical record 
(supplemental Table 1A).
Next, when control and FEP follow-up groups were com-
pared, all the effects remained significant (BMI, HMW and 
total adiponectin, glycosylated hemoglobin, triglyceride and 
HDL cholesterol levels, and abdominal perimeter) (supplemen-
tal Table  1B). Furthermore, BMI was again affected by gender 
(higher in males) and also by age (supplemental Table 1B). HMW 
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adiponectin levels were also related to gender and age (sup-
plemental Table  1B). Triglycerides and HDL cholesterol were 
affected by age and gender, respectively and, finally, abdominal 
perimeter positively corelated both with gender and age (sup-
plemental Table 1B).
Finally, when FEP baseline and follow-up groups were com-
pared, the analysis made was slightly different, including the 
effects of very relevant clinical variables such as the GAF score, 
DDD of antipsychotic medication, and DUP (see supplemental 
Table  1C). The effects observed on E-selectin levels remained 
unaffected for all demographic and clinical factors studied 
(supplemental Table 1C). Adiponectin alterations were affected 
by gender (HMW type) and age (total), and, finally, glycosylated 
hemoglobin alterations were directly related to the existence of 
familiar CV clinical record (supplemental Table 1C).
To further investigative the significant alterations observed 
between baseline and follow-up FEP groups, we carried out a 
complementary regression model that analyzed the change of 
each biological marker (from baseline to the follow-up point) 
depending on the other selected variables. In this approach, we 
also checked the putative effects of the use of the specific antip-
sychotic drugs clozapine and olanzapine, due to their remark-
able capacity to produce metabolic/CV alterations from the time 
of their prescription, as occurred in our conditions.
Using this approach, the difference in total antipsychotic 
equivalents was inversely related to the difference in E-selectin 
plasma levels between both time points studied (for each DDD 
unit increased during this period, E-selectin decreased 7.575 
units during follow-up, after controlling for the effect of the 
increase in the other explanatory variables; see Table 3). In addi-
tion, the difference in the GAF score was also inversely related 
to the difference in both types of adiponectin (for each GAF scale 
unit increased during this period, HMW and total adiponec-
tin levels decreased 0.057 units and 0.069 units, respectively) 
(Table  3). The total adiponectin difference between baseline 
and follow-up was affected by gender (Table 3). The difference 
in glycosylated hemoglobin levels was also inversely related 
to the GAF score between both time-frames studied (for each 
GAF scale unit increased during this period, glycosylated hemo-
globin levels decreased 0.011 units) (Table 3). No specific effects 
of clozapine and olanzapine use on the parameters tested were 
found (Table 3).
Relationship between Pro-/Antiinflammatory 
Mediators and Altered Metabolic and CV Parameters 
in FEP Baseline and Follow-Up Groups
The overactivation of the inflammatory response has been 
related to an increased risk of developing metabolic and CV 
alterations. We previously reported a systemic pro-/antiinflam-
matory dysregulation in our FEP baseline and follow-up groups 
(Garcia-Bueno et al., 2014a, 2014b). Considering this background, 
we applied the Pearson correlation analysis, trying to evalu-
ate whether this inflammatory imbalance could be somehow 
Figure 1. Plasma levels of cardiovascular (CV) factors between first episode of psychosis (FEP) and controls. Mean differences (SD) on VCAM-1 (A), E-Selectin (B), adi-
ponectin high (molecular weight [HMW]) (C), and total adiponectin (D) between controls (C). Baseline and follow-up FEP (for VCAM-1: controls n = 89, baseline n = 99, 
follow-up = 82; for E-selectin and adiponectin [HMW]: controls n = 80, baseline n = 84, follow-up = 82; for total adiponectin: controls n = 40, baseline n = 44, follow-up = 47). 
Two-tailed nonparametric Mann-Whitney U test was used.
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affecting the metabolic and CV alterations found in FEP baseline 
and follow-up groups.
In this way, plasma levels of the proinflammatory media-
tor prostaglandin E2 directly correlated with E-selectin levels 
both in control and FEP baseline groups (Table 4). In addition, 
the activity of the proinflammatory nuclear factor κB (NFκB) 
in peripheral blood mononuclear cells directly correlated with 
both adiponectin HMW and total levels only in the FEP follow-up 
group (Table 4).
The complementary analysis of the antiinflammatory medi-
ators showed that the protein expression of the antiinflam-
matory nuclear peroxisome proliferator-activated receptor γ 
(PPARγ) in peripheral blood mononuclear cells negatively cor-
related with E-selectin levels and positively with VCAM-1 levels 
Table 3. Change of each biological marker (from baseline to the follow-up point) depending on selected demographic and clinical variables. 
Multiple linear regression analysis. Abbreviations: ß, linear regression coefficient; SE, standard error; CI, Confidence interval; OL, over limit; 
LL, Lower limit; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days elapsed 
between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale. The bold 
values in the table represents the values reaching statistical significance (P<.05).
N=53
E-SELECTIN
B SE t CI 95% (OL) CI 95% (LL) p
Gender (ref Female) 1111,603 1894,739 ,587 -2714,900 4938,107 ,561
Age 306,990 162,144 1,893 -20,466 634,446 ,065
Cardiovascular record -887,788 7850,027 -,113 -16741,239 14965,663 ,911
Lithium 439,704 3230,983 ,136 -6085,399 6964,806 ,892
Antipsychotic DDD -7,575 3,347 -2,263 -14,334 -,816 ,029
GAF -51,375 79,835 -0,644 -212,604 109,854 ,523
Cannabis consume 36,459 52,865 ,690 -70,305 143,223 ,494
Cotinin consume -11,371 11,689 -,973 -34,978 12,236 ,336
DUBM 7,477 2,708 2,761 2,008 12,945 ,009
DUP 11,219 12,173 0,922 -13,365 35,802 ,362
Olanzapine+Clozapine -2649,334 2501,065 -1,059 -7700,337 2401,669 ,296
ADIPONECTIN HMW
N=56 B SE t CI 95% (OL) CI 95% (LL) p
Gender (ref Female) -,036 ,618 -,059 -1,281 1,209 ,953
Age -,021 ,050 -,425 -,122 ,080 ,673
Cardiovascular record -0,904 1,638 -,552 -4,204 2,396 ,584
Lithium -,113 1,027 -,110 -2,183 1,957 ,913
Antipsychotic DDD ,001 ,001 1,018 -,001 ,003 ,314
GAF -,057 ,025 -2,272 -,108 -,006 ,028
Cannabis consume -,013 ,016 -,826 -,044 ,018 ,413
Cotinin consume ,000 ,004 ,112 -,007 ,008 ,911
DUBM ,000 ,001 -,238 -,002 ,002 ,813
DUP -0,004 0,004 -0,972 -0,012 0,004 ,336
Olanzapine+Clozapine 0,428 0,777 0,551 -1,138 1,994 ,584
ADIPONECTIN TOTAL
N=24 B SE t CI 95% (OL) CI 95% (LL) p
Gender (ref Female) 2,201 ,557 3,949 0,997 3,404 ,002
Age ,094 ,048 1,967 -,009 ,196 ,071
Cardiovascular record 1,967 1,325 1,485 -0,895 4,829 ,161
Antipsychotic DDD -,001 ,002 -,781 -,005 ,002 ,449
GAF -,069 ,025 -2,800 -,123 -,016 ,015
Cannabis consume ,021 ,025 ,842 -,033 ,076 ,415
Cotinin consume -,003 ,006 -,507 -,015 ,009 ,621
DUBM ,003 ,001 2,504 ,000 ,005 ,026
DUP 0,006 0,003 1,832 -0,001 0,013 ,090
Olanzapine+Clozapine 0,288 1,410 0,205 -2,757 3,333 ,841
GLYCOSYLATED HEMOGLOBLIN
N=52 B SE t CI 95% (OL) CI 95% (LL) p
Gender (ref Female) -,046 ,100 -,465 -0,248 0,155 ,644
Age ,003 ,009 ,346 -,015 ,021 ,731
Cardiovascular record 0,072 0,286 ,252 -0,505 0,650 ,802
Lithium -,205 0,173 -1,187 -0,555 0,144 ,242
Antipsychotic DDD ,000 ,000 -1,228 -,001 ,000 ,227
GAF -,011 ,004 -2,883 -,019 -,003 ,006
Cannabis consume -,003 ,003 -1,053 -,009 ,003 ,299
Cotinin consume ,001 ,001 ,793 -,001 ,002 ,432
DUBM ,000 ,000 ,732 ,000 ,000 ,469
DUP 0,000 0,001 0,124 -0,002 0,002 ,902
Olanzapine+Clozapine -0,105 0,124 -0,849 -0,356 0,145 ,401
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in control conditions (Table  4). Furthermore, in FEP baseline 
conditions, the protein levels PPARγ negatively correlated with 
E-selectin and PPARγ activity directly correlated with total and 
HMW adiponectin (Table 4).
Discussion
In this 6-month follow-up study with FEP subjects, we found 
specific alterations in the levels of classical and novel CV risk/
protection biomarkers at the different time points analyzed. 
The complementary statistical approach made, considering 
the net difference between the values obtained at both tem-
poral points studied for each parameter as dependent vari-
ables, allowed us to find an inverse relationship between the 
difference in total antipsychotic equivalents and the difference 
in E-Selectin plasma levels. In addition, the difference in GAF 
scores was also related to the difference in HMW and total 
adiponectin.
Table  4. Relationship between cardiovascular and metabolic risk and protection factors and systemic pro/anti-inflammatory mediators. 
Multiple linear regression analysis. The bold values in the table represents the values reaching statistical significance (P<.05).
Control NFκB Act COX2 WB PGE2 iNOS WB TBARS PPARy Act PPARy WB 15d-PGJ2 IκBα WB 
Pearson’s 
Coefficient
-0,19 -0,11 0,12 -0,05 -0,01 0,03 0,39 -0,02 -0,13
VCAM-1 Sig (Bilat) 0,118 0,204 0,131 0,564 0,866 0,742 0,041 0,766 0,126
N 67 130 150 131 149 124 28 150 131
Pearson’s 
Coefficient
-0,13 -0,04 0,25 -0,07 0,12 -0,06 -0,43 -0,11 0,00
E-Selectin Sig (Bilat) 0,310 0,654 0,003 0,456 0,145 0,487 0,023 0,182 0,997
N 66 126 146 127 145 120 28 146 127
Pearson’s 
Coefficient
-0,15 -0,07 -0,09 -0,04 0,04 0,11 0,20 -0,06 -0,05
Adiponectin HMW Sig (Bilat) 0,221 0,459 0,289 0,658 0,609 0,221 0,304 0,491 0,547
N 67 123 141 124 140 117 28 141 124
Pearson’s 
Coefficient
-0,38 -0,11 -0,02 -0,14 0,11 0,11 0,13 -0,08 0,05
Adiponectin total Sig (Bilat) 0,074 0,407 0,869 0,282 0,379 0,435 0,729 0,495 0,691
N 23 59 69 60 68 53 10 69 60
FEP’s Baseline NFκB Act COX2 WB PGE2 INOS WB TBARS PPARy Act PPARy WB 15d-PGJ2 IκBα WB 
Pearson’s 
Coefficient
-0,23 -0,11 0,01 0,14 -0,06 -0,07 0,12 0,06 -0,22
VCAM-1 Sig (Bilat) 0,184 0,398 0,947 0,300 0,624 0,642 0,708 0,625 0,100
N 34 58 67 59 66 51 12 67 59
Pearson’s 
Coefficient
-0,21 -0,06 0,27 -0,07 0,05 0,17 -0,64 -0,15 0,01
E-Selectin Sig (Bilat) 0,247 0,673 0,030 0,593 0,671 0,242 0,026 0,233 0,957
N 33 55 64 56 63 48 12 64 56
Pearson’s 
Coefficient
-0,26 -0,20 -0,15 0,01 0,21 0,35 0,26 -0,11 -0,07
Adiponectin HMW Sig (Bilat) 0,143 0,131 0,234 0,955 0,089 0,011 0,406 0,380 0,597
N 34 58 67 59 66 51 12 67 59
Pearson’s 
Coefficient
-0,35 -0,21 -0,17 -0,10 0,23 0,61 0,65 -0,24 -0,01
Adiponectin total Sig (Bilat) 0,197 0,284 0,343 0,593 0,205 0,003 0,351 0,175 0,959
N 15 29 34 30 33 22 4 34 30
FEP’s Follow-up NFκB Act COX2 WB PGE2 INOS WB TBARS PPARy Act PPARy WB 15d-PGJ2 IκBα WB 
Pearson’s 
Coefficient
-0,01 -0,07 0,06 0,08 0,03 0,16 -0,24 -0,10 -0,15
VCAM-1 Sig (Bilat) 0,907 0,518 0,602 0,500 0,767 0,226 0,435 0,413 0,233
N 81 80 81 80 81 56 13 73 62
Pearson’s 
Coefficient
-0,21 -0,08 0,20 0,07 0,18 0,13 -0,42 -0,14 0,05
E-Selectin Sig (Bilat) 0,063 0,459 0,072 0,564 0,101 0,328 0,152 0,242 0,690
N 81 80 81 80 81 56 13 73 62
Pearson’s 
Coefficient
0,34 -0,08 -0,16 -0,02 0,10 -0,07 -0,04 0,07 -0,19
Adiponectin HMW Sig (Bilat) 0,002 0,493 0,161 0,875 0,363 0,603 0,896 0,579 0,140
N 81 80 81 80 81 56 13 73 62
Pearson’s 
Coefficient
0,35 -0,13 -0,13 0,07 0,10 0,06 0,49 -0,30 0,00
Adiponectin total Sig (Bilat) 0,018 0,389 0,375 0,662 0,527 0,793 0,404 0,065 0,991
N 46 45 46 45 46 25 5 38 31
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Finally, we also analyzed the possible relationship between 
CV risk/protective factor and pro-/antiinflammatory mediators. 
E-selectin levels were related to the levels of the proinflamma-
tory mediator prostaglandin E2 both in control and FEP baseline 
groups. NFκB activity directly correlated with both HMW and 
total adiponectin levels only in the FEP follow-up group. In the 
case of antiinflammatory mediators, the protein levels PPARγ 
negatively correlated with E-selectin and PPARγ activity directly 
correlated with total adiponectin in the FEP baseline group.
Patients with chronic SZ present an increased susceptibil-
ity for suffering cardiac complications and even sudden cardiac 
death than the general population (Jindal et  al., 2005); conse-
quently, one of the fields of research is the study of CV risk and 
protection biomarkers, not only in full-blown SZ but also in ear-
lier clinical manifestations and even in the prodromal phase. It 
is worth mentioning that the levels of all classical risk metabolic 
and CV factors studied in our cohort of FEP patients were in the 
normal range for subjects with a mean age of approximately 
25 years, although we found some concomitant significant dif-
ferences between groups that taken as a whole, could anticipate 
possible deleterious consequences in the physical condition of 
the FEP patients included in our study. The use of ratios between 
triglycerides, HDL and low density lipoprotein cholesterol to 
identify insulin resistance early in FEP patients of different 
gender is an interesting approach to explore in future studies 
(Quispe et al., 2016).
We have described a state in our cohort of FEP baseline sub-
jects characterized by increased triglycerides and abdominal 
perimeter and decreased HDL cholesterol levels compared with 
control subjects. These alterations were also found in the fol-
low-up group, and, in addition, FEP follow-up patients showed 
increased levels of glycosylated hemoglobin compared with 
both control and FEP basal groups. In this way, glycosylated 
hemoglobin could be considered a state biomarker, as the other 
trait biomarkers in our experimental conditions.
Previous studies identified the increased levels of glycosylated 
hemoglobin in plasma as a biomarker of poor control of blood 
glucose levels associated with CV alterations in FEP subjects with 
negative results (Phutane et  al., 2011), although other glucose-
metabolism related measures suggested, at least in one of the 
studies, that drug-naïve FEP subjects were more insulin resistant 
compared with matched controls (Petrikis et al., 2015). A recent 
meta-analysis corroborated that glycosylated hemoglobin levels 
were not altered in FEP patients compared with controls; how-
ever, other glucose metabolism-related parameters were clearly 
affected, suggesting an early impairment in this system (Pillinger 
et al., 2017). In chronic SZ, the increase in plasma glycosylated 
hemoglobin levels is well described (Balotsev et al., 2017). In add-
ition to these results, the inverse relationship between the GAF 
score and glycosylated hemoglobin plasma levels found with our 
regression models supports the idea suggested by some authors 
that routine testing of glycosylated hemoglobin could be help-
ful for early detection of diabetes in psychotic inpatients and its 
relationship to symptomatology (Hinds et al., 2015; Steylen et al., 
2015; Naidu et al., 2017).
Regarding the CV risk factors studied, the effects observed 
on E-selectin are the most relevant, because our multiple lin-
ear regression analysis suggested that antipsychotic medication 
from baseline to follow-up groups could be related to the restored 
levels of E-selectin observed in FEP follow-up subjects. In previ-
ous longitudinal studies, there is some controversy: FEP subjects 
treated for 24 weeks with antipsychotics showed increased lev-
els of E-selectin compared with the onset of treatment (Graham 
et al., 2008), but in FEP subjects under antipsychotic medication 
for 3 months, patients treated with perphenazine, risperidone, 
and ziprasidone showed decreased levels of E-selectin in plasma 
compared with the baseline group (Meyer et al., 2009). It is worth 
mentioning that, in agreement with our report, patients treated 
with olanzapine or quetiapine did not present decreased lev-
els of E-selectin in the 3-month follow-up, suggesting that each 
antipsychotic drug could be differentially affecting endothelial 
dysfunction and inflammation in pathological conditions.
The decreased levels of the CV protective factor adiponec-
tin in the plasma of FEP follow-up patients compared with both 
control and FEP baseline groups also deserve further discussion. 
As in the case of E-selectin, some contradictory results have 
been reported. One study agreed with ours showing decreased 
levels of adiponectin in plasma samples of FEP subjects under 
antipsychotic medication for 24 weeks compared with the 
onset of treatment (Graham et  al., 2008). However, high levels 
in drug-naive FEP patients (Song et al., 2013) or no changes on 
adiponectin levels after 1 year of treatment with antipsychotics 
in drug-naive FEP patients (Perez-Iglesias et al., 2008) have also 
been reported. A  recent meta-analysis reported that subjects 
with SZ may not have lower levels of adiponectin than controls, 
but the specific treatment with olanzapine decreased adiponec-
tin levels compared with other antipsychotics (Bartoli et  al., 
2015). However, the results derived from our statistical approach 
did not support a specific effect of olanzapine or clozapine on 
the observed reduced levels of adiponectin between FEP base-
line and follow-up groups.
To our knowledge, there are no studies evaluating the asso-
ciation between adiponectin levels and GAF score in psychotic 
patients. Our results are contra-intuitive, taking into account 
that adiponectin is accepted as a protective mediator. It is worth 
mentioning that our patients presented improved symptoma-
tology measured by several clinical scales (GAF included) in the 
follow-up group compared with the baseline group. Thus, our 
results could suggest a relationship between adiponectin and 
global functioning, at least in early FEP, but its nature as well 
as the putative effects of other confounding factors needs to be 
further corroborated in future studies.
Finally, we took advantage of previous studies evaluating the 
state of pro-/antiinflammatory mediators in the same cohorts of 
FEP patients and controls used here (Garcia-Bueno et al., 2014a, 
2014b) to evaluate their putative relationship with VCAM-1, 
E-selectin, and adiponectin levels. We reported a direct correla-
tion between NFκB activity and adiponectin only in the FEP fol-
low-up group. The relationship between both factors is complex 
and the effects of adiponectin on NFκB depend on the isoform 
studied (Adya et al., 2015). Interestingly, the isoform HMW (that 
was specifically measured in our study) activated nuclear fac-
tor NFκB-mediated gene expression of the E-selectin promoter 
in adipocytes in vitro (Tsao et al., 2002), an effect that could be 
related to the decrease in E-selectin observed in the FEP follow-
up group. The activation of NFκB by HMW-adiponectin has been 
also described in vascular endothelial cells and monocyte/
macrophage U937 cells (Haugen and Drevon, 2007; Tomizawa 
et  al., 2008). Indeed, further studies measuring the different 
adiponectin species are needed to elucidate the regulatory role 
of adiponectin on proinflammatory pathways, such as the one 
orchestrated by NFκB.
The correlation with antiinflammatory mediators only 
appeared with PPARγ and in the control and FEP baseline groups. 
The increased levels of E-selectin could be related to PPARγ 
expression downregulation as the inverse nature of their correla-
tion suggests. PPARγ genetic or pharmacological positive modu-
lation inhibited E-selectin expression in human endothelial cells 
Downloaded from https://academic.oup.com/ijnp/article-abstract/21/5/410/4706298
by Universidad de Zaragoza user
on 15 June 2018
420 | International Journal of Neuropsychopharmacology, 2018
both in vitro and in vivo (Wang et al., 2002; Genovese et al., 2013), 
although some negative results also exist (Pasceri et al., 2000).
In the FEP baseline group, total and HMW adiponectin were 
directly related to PPARγ activity. It is worth mentioning that 
adiponectin levels were not significantly different than in con-
trols but were higher than in the FEP follow-up group. Whether 
a sustained level of adiponectin in the baseline group is related 
to PPARγ activity needs to be corroborated in future studies, but 
it has been recently described that adiponectin is induced by the 
pharmacological activation of PPARγ with the synthetic ligand 
rosiglitazone, affecting stress and negative emotion-related 
behaviors in rats submitted to a depression-like model (Guo 
et  al., 2017). Future studies with larger cohorts are needed to 
evaluate the interactions between inflammation and metabolic 
syndrome considered as a whole clinical entity for cardiovas-
cular disturbances in FEP, as they have been already studied in 
SZ (Leonard et  al., 2012) and other neuropsychiatric disorders 
(Nousen et al., 2013).
The present study presents several limitations: (1) most 
patients were under antipsychotic treatment for several months 
before blood extraction for biochemical determinations; (2) as 
it was a naturalistic study, not a randomized controlled trial, 
patients could be changing treatments during the follow-up 
period according to the clinician’s choice; (3) all the participant 
sites are tertiary care centers linked to the Spanish network of 
translational research (CIBERSAM), so patient samples and thera-
peutic strategies may differ from those used in other areas; (4) 
a previous sample size calculation was not made. This calcula-
tion could have improved the design of the study and, in the case 
of a larger number of samples, we had probably found statistical 
differences in other variables, such as for example in E-selectin 
levels; (5) Control subjects were not followed 6 months after base-
line as in case of FEP patients, and this limitation should be taken 
into account; and (6) there are statistically significant differences 
in BMI index between control and FEP patients. However, from a 
clinical point of view, all the subjects were in the range of normal-
ity following the BMI classical classification and thus, we consider 
that there are not significant clinical differences that could be 
decisively affecting the rest of results here reported.
In summary, we report here subtle but concomitant altera-
tions of classical CV and metabolic risk factors in a cohort of FEP 
patients at the first onset of positive psychotic symptoms and 
at 6 months. Glycosylated hemoglobin emerged as a potentially 
relevant state biomarker for the diagnosis due to its relationship 
to the GAF score. In addition, among novel CV risk and protec-
tive factors analyzed, we concluded that alterations in plasma 
adiponectin levels could be a good clinical index, reflecting the 
degree of severity of the symptomatology. Our results support 
the need for integrating CV health care very early after the FEP.
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